Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
2012 StandoutScience
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
The transcriptional repressor Snail promotes mammary tumor recurrence
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: A population-based study of 4317 women diagnosed in Denmark 1978–2006
2012
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Dual-specificity MAP kinase phosphatases (MKPs) and cancer
2008
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
2009
Breast cancer
2016 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Ovarian cancer biomarkers for molecular biosensors and translational medicine
2010
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
Chemotaxis in cancer
2011
Ovarian cancer
2014 Standout
EMT and Dissemination Precede Pancreatic Tumor Formation
2012 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review
2009
Colorectal cancer
2013 Standout
Antitumour actions of interferons: implications for cancer therapy
2016
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Activation-Induced Cytidine Deaminase Links Between Inflammation and the Development of Colitis-Associated Colorectal Cancers
2008 StandoutNobel
Role of Hypoxia-Inducible Factor 1 in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation
2004 StandoutNobel
The impact of T‐cell immunity on ovarian cancer outcomes
2008
Revealing the human mucinome
2022 StandoutNobel
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Circulating tumour cells in non-metastatic breast cancer: a prospective study
2012
Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice
2004
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
2011
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)
2011
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Superficially invasive squamous cell carcinoma of the cervix
1992
Cancer treatment and survivorship statistics, 2012
2012 Standout
EMT: 2016
2016 Standout
Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer
2007
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
2008 Standout
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)
2007
Dormancy in breast cancer
2012
Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer
2014
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines
2015
The basics of epithelial-mesenchymal transition
2009 Standout
Recent progress in the diagnosis and treatment of ovarian cancer
2011
Molecular mechanisms of metastasis in breast cancer—clinical applications
2010
Surgical results of pelvic exenteration in the treatment of gynecologic cancer
2014
New modalities in detection of recurrent ovarian cancer
2004
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Cervical cancer
2019 Standout
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
2006
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
2011
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
2014
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
The ascites N-glycome of epithelial ovarian cancer patients
2017
Update of randomized trials in recurrent disease
2011
RNA–protein analysis using a conditional CRISPR nuclease
2013 StandoutNobel
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
2014
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
2011
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
2015
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Lysosomal cathepsin D mediates endogenous mucin glycodomain catabolism in mammals
2022 StandoutNobel
Breast Cancer Treatment
2019 Standout
Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.
2001
Laparoscopic vaginal radical trachelectomy
2000
Cancer Genome Landscapes
2013 StandoutScience
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone
2016
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2006
Works of W. Lichtenegger being referenced
The prognostic significance of epithelial-mesenchymal transition in breast cancer.
2003
p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian Carcinoma
2000
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
2003
The importance of parametrial lymph nodes in the treatment of cervical cancer
1989
Systematic Evaluation of the Intraoperative Tumor Pattern in Patients With Borderline Tumor of the Ovary
2009
Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO
2007
Prognostic Significance of DNA Content and S-Phase Fraction in Epithelial Ovarian Carcinomas Analyzed by Image Cytometry
1998
Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients
2010
„IMO” - Intraoperatives Mapping des Ovarialkarzinoms
2003
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial
2006
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
2014
Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer
2008
Intra‐abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer
2009
Long‐term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies
2010
Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients
2010
Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer
2003
Operative Results after Primary and Secondary Debulking‐Operations in Advanced Ovarian Cancer (AOC)
1998
Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma
2002
Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.
2010
Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.
2009
Polymorphism of IL-1 receptor antagonist gene: role in cancer.
2003
Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients
2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
2010
Expression of IL-10 in patients with ovarian carcinoma.
2006
Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial.
2010
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
2008